exelixis news - Search News

MSN, Exel

Exelixis Gets Favorable Ruling in Patent Litigation With MSN

Exelixis, Inc. EXEL announced that the District Court of Delaware has ruled in its favor in the second patent litigation against MSN Laboratories. MSN is seeking approval for its generic product of Exelixis’ cabozantinib.

Business Wire · 1d

Exelixis Announces Update on Second Patent Litigation Trial with MSN Laboratories

Exelixis, Inc. (Nasdaq: EXEL) today announced that in the lawsuit Exelixis, Inc. (Exelixis) vs. MSN Laboratories Private Limited et al. (MSN), Civil A

Seeking Alpha on MSN · 2d

Exelixis gains after win in patent fight with MSN over Cabometyx

Exelixis (NASDAQ:EXEL) jumped 6% after winning in a patent fight with generic drug make MSN Laboratories over Cabometyx. The asserted claim of the '349 patent not infringed and not invalid, Judge Richard Andrews ruled, according to a court filing on Tuesday.

MarketWatch · 2d

Exelixis' Wins Court Ruling in Patent-Infringement Lawsuit

A court ruled in favor of Exelixis in the oncology company's patent-infringement lawsuit against MSN Laboratories.

Zacks.com on MSN1d

Exelixis (EXEL) Soars 8.6%: Is Further Upside Left in the Stock?

Exelixis (EXEL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate ...

FiercePharma1d

Exelixis stock rises as key drug Cabometyx withstands patent challenge

A federal judge in Delaware has ruled in favor of Exelixis in its Cabometyx patent fight with MSN Laboratories, effectively ...

Exelixis Hold Rating: Navigating Legal Wins and Strategic Acquisitions Amid Uncertain Revenue Transition

Exelixis (EXEL – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Stephen Willey ...

Zacks.com on MSN2d

Exelixis, MRK Collaborate for Combination Studies on HNSCC and RCC

Exelixis, Inc. EXEL entered into a clinical development collaboration agreement with pharma giant Merck MRK to advance the ...

bovnews2d

Exelixis (EXEL) Sees Notable Gains in Today’s Trading: What’s Behind the Surge?

In addition to the legal success, Exelixis has received an upgrade from B of A Securities. The firm has maintained a Buy rating and raised the price target from $30 to $32. This optimistic outlook ...

18h

RBC Capital Keeps Their Buy Rating on Exelixis (EXEL)

RBC Capital analyst Gregory Renza maintained a Buy rating on Exelixis (EXEL – Research Report) yesterday and set a price target of ...

Pharmabiz2d

Exelixis, Merck enter clinical development collaboration to evaluate zanzalintinib in combo with Keytruda in HNSCC and in combo with Welireg in RCC

Alameda, California Tuesday, October 15, 2024, 14:00 Hrs [IST] ...

bovnews2d

Exelixis Inc’s Stock Drama: Could This Be a Game-Changer for EXEL Investors?

On Monday, Exelixis Inc (EXEL) stock saw a modest uptick, ending the day at $26.24 which represents a slight increase of $0.01 or 0.04% from the prior close of $26.23. The stock opened at $26.23 and ...

Zacks.com on MSN5h

Biotech Stock Roundup: VNDA, JAZZ Up on Updates, NVAX Suffers Setback & More

Last week, the biotech sector was in focus, with regular pipeline and regulatory updates. Vanda Pharmaceuticals Inc. VNDA was ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results

Related topics